The Validation of a Novel Adherence Method for Oral Oncolytics

Overview

The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics and to validate a currently available smart phone application (iRxReminder) partnered with an automated dispensing device, a "Pod", in affecting patient adherence. The rationale for this study is that medication adherence to oncolytics varies and strategies are needed to improve it.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 31, 2018

Interventions

  • Other: Smart Phone Application
    • Oral medication adherence phone application.
  • Other: POD
    • Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.

Arms, Groups and Cohorts

  • No Intervention: Standard Patient Reported Adherence
    • Adherence assessment via phone call or in person
  • Active Comparator: Smart Phone Application
    • Adherence assessment via phone app
  • Experimental: POD and Smart Phone Application
    • Adherence assessment via phone app partnered with an automated dispensing machine, a “Pod.”

Clinical Trial Outcome Measures

Primary Measures

  • The change in the number of patients that report high adherence over time via smart phone application alone
    • Time Frame: 0, 4, 8 and 12 weeks
    • Adherence will be assessed via smart phone application at baseline, 4, 8 and 12 weeks. Adherence reported via the phone application will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent).
  • The change in the number of patients that report high adherence over time via smart phone application and POD
    • Time Frame: 0, 4, 8 and 12 weeks
    • Adherence will be assessed via smart phone application + POD at baseline, 4, 8 and 12 weeks. Adherence reported via the phone application will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). For the Pod there will be continuous adherence assessed via the pod each time the patient administers or does not administer a scheduled dose. This will be figured into the overall adherence rating.
  • The change in the number of patients that report high adherence over time via telephone/face-to-face visit (self-reported)
    • Time Frame: 0, 4, 8 and 12 weeks
    • Adherence will be assessed via telephone/face-to-face visit (self-reported) at baseline, 4, 8 and 12 weeks. Self-reported adherence will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent).

Participating in This Clinical Trial

Inclusion Criteria

  • Must be > 18 years of age
  • Must have a smart phone
  • Must be able to have their oral oncolytic filled at the University of Michigan Comprehensive Cancer Center pharmacy and be newly prescribed Capecitabine (Xeloda).

Exclusion Criteria

  • Patients who do not have a smart phone
  • Patients who have a serious mental illness or cognitive impairment, e.g., psychosis or dementia.
  • Patients who do not speak English
  • Patients who cannot fill their oral oncolytic prescription at the University of Michigan Comprehensive Cancer Center Pharmacy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Michigan Rogel Cancer Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shawna Kraft, Pharm.D., BCOP, Principal Investigator, University of Michigan Rogel Cancer Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.